Ann Eldred

579 total citations
19 papers, 395 citations indexed

About

Ann Eldred is a scholar working on Immunology, Rheumatology and Hematology. According to data from OpenAlex, Ann Eldred has authored 19 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Rheumatology and 10 papers in Hematology. Recurrent topics in Ann Eldred's work include Psoriasis: Treatment and Pathogenesis (14 papers), Spondyloarthritis Studies and Treatments (10 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Ann Eldred is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Spondyloarthritis Studies and Treatments (10 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Ann Eldred collaborates with scholars based in United States, Canada and Germany. Ann Eldred's co-authors include Kim Papp, Ahmed M. Soliman, Wenjing Lü, Frank Behrens, Zailong Wang, Douglas White, Lars Erik Kristensen, Mauro Waldemar Keiserman, Alan Kivitz and Andrew J.K. Östör and has published in prestigious journals such as Journal of Biological Chemistry, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Ann Eldred

19 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Eldred United States 9 264 225 161 64 43 19 395
Gerd-Marie Alenius Sweden 10 388 1.5× 493 2.2× 232 1.4× 32 0.5× 118 2.7× 18 618
Kara Rice United States 8 145 0.5× 18 0.1× 189 1.2× 72 1.1× 40 0.9× 16 309
Mitsuha Hayashi Japan 9 241 0.9× 51 0.2× 32 0.2× 112 1.8× 11 0.3× 11 305
Guifen Shen China 8 46 0.2× 48 0.2× 42 0.3× 49 0.8× 62 1.4× 15 280
Jessica Neely United States 10 57 0.2× 61 0.3× 72 0.4× 9 0.1× 26 0.6× 15 206
Maura Couto Portugal 7 145 0.5× 128 0.6× 27 0.2× 11 0.2× 18 0.4× 20 230
M. D. Lockshin United States 8 117 0.4× 205 0.9× 86 0.5× 5 0.1× 19 0.4× 14 291
M J Grange France 6 64 0.2× 84 0.4× 115 0.7× 23 0.4× 18 0.4× 11 327
C. R. Austin United States 9 61 0.2× 72 0.3× 20 0.1× 24 0.4× 51 1.2× 11 286
Noemí Eirís Spain 10 313 1.2× 100 0.4× 36 0.2× 162 2.5× 38 0.9× 21 413

Countries citing papers authored by Ann Eldred

Since Specialization
Citations

This map shows the geographic impact of Ann Eldred's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Eldred with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Eldred more than expected).

Fields of papers citing papers by Ann Eldred

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Eldred. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Eldred. The network helps show where Ann Eldred may publish in the future.

Co-authorship network of co-authors of Ann Eldred

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Eldred. A scholar is included among the top collaborators of Ann Eldred based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Eldred. Ann Eldred is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kikuchi, R., Yuli Qian, Mohamed Badawi, et al.. (2024). Coproporphyrin‐I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug–Drug Interactions: Cedirogant Case Study. Clinical Pharmacology & Therapeutics. 116(5). 1334–1342. 4 indexed citations
2.
D’Cunha, Ronilda, Laura K. Ferris, Ann Eldred, et al.. (2023). 43882 Pharmacokinetics, Safety, and Efficacy of Cedirogant (ABBV-157) in Patients With Moderate-to- Severe Plaque Psoriasis. Journal of the American Academy of Dermatology. 89(3). AB206–AB206. 1 indexed citations
3.
Mohamed, Mohamed‐Eslam F., Yuli Qian, Ronilda D’Cunha, et al.. (2023). Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clinical and Translational Science. 17(1). e13682–e13682. 7 indexed citations
4.
Mease, Philip J., Herbert Kellner, Akimichi Morita, et al.. (2022). Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatology and Therapy. 9(5). 1361–1375. 11 indexed citations
5.
Kristensen, Lars Erik, Mauro Waldemar Keiserman, Kim Papp, et al.. (2022). Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Lara D. Veeken. 62(6). 2113–2121. 23 indexed citations
6.
7.
Kristensen, L. E., et al.. (2022). The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2. Journal of the European Academy of Dermatology and Venereology. 36(11). 2120–2129. 4 indexed citations
8.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2022). Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Lara D. Veeken. 62(6). 2122–2129. 22 indexed citations
9.
Kristensen, Lars Erik, Ahmed M. Soliman, Kim Papp, et al.. (2022). Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Lara D. Veeken. 62(2). 629–637. 7 indexed citations
10.
Östör, Andrew J.K., Ahmed M. Soliman, Kim Papp, et al.. (2022). Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 8(2). e002286–e002286. 7 indexed citations
11.
Kristensen, Lars Erik, Mauro Waldemar Keiserman, Kim Papp, et al.. (2021). Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the Rheumatic Diseases. 81(2). 225–231. 99 indexed citations
12.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2021). Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Annals of the Rheumatic Diseases. 81(3). 351–358. 79 indexed citations
13.
14.
15.
Mease, Philip J., H. Kellner, Akimichi Morita, et al.. (2018). OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Annals of the Rheumatic Diseases. 77. 200–201. 42 indexed citations
16.
Webb, Nicholas J.A., Gary Lerner, Bradley A. Warady, et al.. (2017). Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatric Nephrology. 32(7). 1221–1232. 7 indexed citations
17.
McCullough, Peter A., Elliott Bennett‐Guerrero, Lakhmir S. Chawla, et al.. (2016). ABT‐719 for the Prevention of Acute Kidney Injury in Patients Undergoing High‐Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial. Journal of the American Heart Association. 5(8). 28 indexed citations
18.
Spokes, Katherine, et al.. (1999). Activated ERK2 Interacts with and Phosphorylates the Docking Protein GAB1. Journal of Biological Chemistry. 274(51). 36362–36368. 35 indexed citations
19.
Dubrow, Robert, et al.. (1992). Fecal lysozyme: an unreliable marker for colorectal cancer.. PubMed. 87(5). 617–21. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerd-Marie Alenius Breakdown of academic impact, for papers by Kara Rice Breakdown of academic impact, for papers by Mitsuha Hayashi Breakdown of academic impact, for papers by Guifen Shen Breakdown of academic impact, for papers by Jessica Neely Breakdown of academic impact, for papers by Maura Couto Breakdown of academic impact, for papers by M. D. Lockshin Breakdown of academic impact, for papers by M J Grange Breakdown of academic impact, for papers by C. R. Austin Breakdown of academic impact, for papers by Noemí Eirís
Rankless by CCL
2026